Susquehanna Fundamental Investments’s Amicus Therapeutics FOLD Stock Holding History

Susquehanna Fundamental Investments’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$303K	Sell	31,946 -198,240	-86%	-$1.86M	0.01%	1262
2021 Q4	$2.66M	Buy	230,186 +88,794	+63%	+$990K	0.07%	348
2021 Q3	$1.35M	Buy	141,392 +12,962	+10%	+$133K	0.02%	743
2021 Q2	$1.24M	Buy	128,430 +113,068	+736%	+$1.1M	0.02%	761
2021 Q1	$152K	Sell	15,362 -122,986	-89%	-$1.9M	﹤0.01%	1425
2020 Q4	$3.19M	Sell	138,348 -674	-0.5%	-$13.8K	0.06%	477
2020 Q3	$1.96M	Buy	139,022 +56,822	+69%	+$828K	0.06%	437
2020 Q2	$1.24M	Buy	+82,200	New	+$1M	0.06%	397

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna Fundamental Investments's FOLD Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its Amicus Therapeutics (FOLD) stake by 86% in Q1 2022, selling an estimated $1.86M and leaving 31,946 shares worth $303K. The position accounts for 0.01% of the portfolio, ranked #1262.

Susquehanna Fundamental Investments first reported a position in FOLD in Q2 2020 and has held it in 8 quarters since. The position peaked at $3.19M in Q4 2020. 217 funds tracked by Wall St. Rank hold FOLD as of Q1 2022.

Susquehanna Fundamental Investments held 31,946 shares of Amicus Therapeutics worth $303K as of Q1 2022.
Susquehanna Fundamental Investments sold 198,240 Amicus Therapeutics shares in Q1 2022, an estimated $1.86M.
Amicus Therapeutics made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1262 holding.
Susquehanna Fundamental Investments first reported a position in Amicus Therapeutics in Q2 2020 and has held it in 8 quarters since.
Susquehanna Fundamental Investments's Amicus Therapeutics position peaked at $3.19M in Q4 2020.
217 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.